Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: A report from the Insulin Diabetes Angioplasty study

Diabetes and Vascular Disease Research

Volumn 6, Issue 2, 2009, Pages 71-79

  Hage, Camilla ^a,c   Norhammar, Anna ^a   Grip, Lars ^b   Malmberg, Klas ^a   Sarkar, Nondita ^a   Svane, Bertil ^a   Rydén, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood glucose; Diabetes mellitus; Insulin; Percutanous coronary intervention; Restenosis

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NEUTRAL INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; RESTENOSIS; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68349086694     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109336042     Document Type: Article

References (25)

1. Rydén, L, Standl, E, Bartnik, M, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136. (Pubitemid 46137814)
2. West, NE, Ruygrok, PN, Disco, CM, et al. (2004) Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109: 867-873 (Pubitemid 38252739)
3. Abizaid, A, Costa, MA, Centemero, M, et al. (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104: 533-538 (Pubitemid 32738121)
4. Jimenez-Quevedo, P, Sabate, M, Angiolillo, DJ, et al. (2007) Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 28: 1946-1952 (Pubitemid 47579538)
5. Aronson, D, Bloomgarden, Z, Rayfield, EJ (1996) Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27: 528-535 (Pubitemid 26081914)
6. Muhlestein, JB, Anderson, JL, Horne, BD, et al. (2003) Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 146: 351-358
7. Norhammar, AM, Rydén, L, Malmberg, K (1999) Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 22: 1827-1831
8. Suleiman, M, Hammerman, H, Boulos, M, et al. (2005) Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 111: 754-760 (Pubitemid 40250636)
9. Worthley, MI, Shrive, FM, Anderson, TJ, Traboulsi, M (2007) Prognostic implication of hyperglycemia in myocardial infarction and primary angioplasty. Am J Med 120: 643 e1-7.
10. UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
11. Malmberg, K, Rydén, L, Efendic, S, et al. (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57-65.
12. Van den Berghe, G, Wouters, PJ, Bouillon, R, et al. (2003) Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31: 359-366 (Pubitemid 36232926)
13. Hoelzel, W, Weykamp, C, Jeppsson, JO, et al. (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50: 166-174 (Pubitemid 38125714)
14. Serruys, PW, van Hout, B, Bonnier, H, et al. (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352: 673-681 (Pubitemid 28398701)
15. Almagor, Y, Feld, S, Kiemeneij, F, et al. (1997) First international new intravascular rigid-flex endovascular stent study (FINESS): clinical and angiographic results after elective and urgent stent implantation. The FINESS Trial Investigators. J Am Coll Cardiol 30: 847-854 (Pubitemid 27435872)
16. Chesebro, JH, Knatterud, G, Roberts, R, et al. (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76: 142-154 (Pubitemid 17093202)
17. Lee, MS, Jamal, F, Kedia, G, et al. (2007) Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. Int J Cardiol 123: 34-42. (Pubitemid 350119876)
18. De Luca, L, De Persio, G, Minati, M, Iacoboni, C, Fedele, F (2005) Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. Am Heart J 149: 1135. (Pubitemid 40848162)
19. Lindsay, J, Sharma, AK, Canos, D, et al. (2007) Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovasc Revasc Med 8: 15-20. (Pubitemid 46216178)
20. Corpus, RA, George, PB, House, JA, et al. (2004) Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43: 8-14.
21. Mazeika, P, Prasad, N, Bui, S, Seidelin, PH (2003) Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 145: 1013-1021 (Pubitemid 36688252)
22. Diedrichs, H, Pfister, R, Hagemeister, J, et al. (2008) An increase in HbA1c after percutaneous coronary intervention raises the risk for restenosis in patients without Type 2 diabetes mellitus. Diabet Med 25: 228-231 (Pubitemid 351293394)
23. Creager, MA, Luscher, TF, Cosentino, F, Beckman, JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108:1527-1532 (Pubitemid 37176462)
24. Malmberg, K, Rydén, L, Wedel, H, et al. (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26: 650-661
25. Cheung, NW, Wong, VW, McLean, M (2006) The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 29: 765-770